Holen Sie sich die Stockscreener-App
22.08
1.34%
-0.30
Handel nachbörslich:
22.08
Schlusskurs vom Vortag:
$22.38
Offen:
$22.52
24-Stunden-Volumen:
1.33M
Relative Volume:
1.11
Marktkapitalisierung:
$1.47B
Einnahmen:
$5.79M
Nettoeinkommen (Verlust:
$-199.61M
KGV:
-7.3355
EPS:
-3.01
Netto-Cashflow:
$-188.48M
1W Leistung:
-1.69%
1M Leistung:
+0.59%
6M Leistung:
+8.71%
1J Leistung:
-44.70%
1-Tages-Spanne:
$21.71
$23.02
1-Wochen-Bereich:
$21.34
$23.27
52-Wochen-Spanne:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
22.08 | 1.49B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Backtesting results for Celldex Therapeutics Inc. trading strategiesLong Setup & Reliable Breakout Stock Forecasts - Newser
Analyzing recovery setups for Celldex Therapeutics Inc. investorsPortfolio Update Report & Weekly Setup with ROI Potential - Newser
Is Celldex Therapeutics Inc. stock poised for growthMarket Activity Recap & Daily Technical Forecast Reports - Newser
How Celldex Therapeutics Inc. stock performs during market volatilityGap Down & Free AI Powered Buy and Sell Recommendations - Newser
Custom strategy builders for tracking Celldex Therapeutics Inc.Portfolio Update Report & Free Expert Verified Stock Movement Alerts - Newser
What technical models suggest about Celldex Therapeutics Inc.’s comebackBond Market & AI Driven Price Forecasts - Newser
Celldex Therapeutics Inc. Shows Early Signs of Technical Strength2025 Volume Leaders & Precise Swing Trade Alerts - beatles.ru
How to read the order book for Celldex Therapeutics Inc.2025 Performance Recap & High Accuracy Trade Alerts - Newser
Is now a turning point for Celldex Therapeutics Inc.2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Can volume confirm reversal in Celldex Therapeutics Inc.Weekly Profit Summary & Step-by-Step Swing Trade Plans - Newser
Institutional scanner results for Celldex Therapeutics Inc.2025 Price Momentum & High Return Stock Watch Alerts - Newser
What indicators show strength in Celldex Therapeutics Inc.July 2025 Price Swings & Daily Chart Pattern Signal Reports - Newser
Will Celldex Therapeutics Inc. continue its uptrendMarket Rally & High Conviction Buy Zone Alerts - Newser
Is Celldex Therapeutics Inc. impacted by rising ratesTrade Analysis Summary & Technical Pattern Recognition Alerts - sundaytimes.kr
Can Celldex Therapeutics Inc. hit a new high this month2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
How to build a dashboard for Celldex Therapeutics Inc. stockEarnings Growth Report & Smart Investment Allocation Insights - Newser
Combining machine learning predictions for Celldex Therapeutics Inc.Weekly Trade Report & Community Consensus Picks - Newser
News impact scoring models applied to Celldex Therapeutics Inc.Weekly Market Report & Daily Chart Pattern Signals - Newser
Live market analysis of Celldex Therapeutics Inc.Earnings Beat & Weekly High Potential Stock Alerts - Newser
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses - MSN
Published on: 2025-08-29 21:03:23 - Newser
Chart based analysis of Celldex Therapeutics Inc. trendsJuly 2025 Trends & AI Driven Price Forecasts - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):